Helicobacter Pylori Eradication Antibiotic
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Livzon PharmaceuticalChina - Zhuhai
1 program1
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapyPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Livzon PharmaceuticalIlaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy
Clinical Trials (1)
Total enrollment: 100 patients across 1 trials
NCT02835560Livzon PharmaceuticalIlaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
Start: Jun 2013100 patients
Phase 4Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.